Xinyang Du

Xinyang Du

Auto-generated profile, based on publicly available information

Xinyang Du

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Shanghai, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XZXiaojuan Zhang
Xiaojuan Zhang
MZMina Zhang
Mina Zhang
XDXinyang Du
Xinyang Du
GZGuowei Zhang
Guowei Zhang
YNYuanyuan Niu
Yuanyuan Niu
HWHuijuan Wang
Huijuan Wang
Background: This study aims to determine the efficacy and safety profile of aumolertinib in the real-word treatment setting for advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations.Methods: We retrospectively analyzed the clinical data of 173 EGFR-mutated advanced NSCLC patients who received aumolertinib treatment at Henan Cancer Hospital from April 2020 to December 2022. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier survival curves, while a Cox regression model was used for multifactorial analysis and prognostic factor assessment.Results: Among patients administered first-line aumolertinib (n = 77), the objective remission rate (ORR) of 77.92% was observed, along with a disease control rate (DCR) of 100%. The median progression-free survival (mPFS) was 24.97 months, which did not reach the median overall survival (mOS). The patients treated with aumolertinib after progression on prior EGFR-tyrosine kinase inhibitor (TKI) therapy (n = 96) exhibited an ORR of 46.88%, a DCR of 89.58%, an mPFS of 15.17 months, and an mOS of 21.27 months. First-line treatment multivariate Cox regression analysis demonstrated a statistically significant impact of elevated creatine kinase on PFS (p = 0.016) and a similar significant influence of co-mutation on OS (p = 0.034). Furthermore, subsequent-line treatment multivariate Cox regression analysis showed a statistically significant impact of elevated creatine kinase on median PFS (p = 0.026) and a significant effect on the number of metastatic organs (p = 0.017), co-mutation (p = 0.035), and elevated creatine kinase (p = 0.014) on median OS.Conclusion: Aumolertinib has shown clinical significance and can safely be used in the real-world setting for patients with EGFR mutation-positive NSCLC.

28 March 2022 in Thoracic Cancer
Verified
Journal Article
Open access
XDXinyang Du
Xinyang Du
HBHua Bai
Hua Bai
ZWZhijie Wang
Zhijie Wang
JDJian Chun Duan
Jian Chun Duan
ZLZheng Liu
Zheng Liu
JWjie wang
jie wang
Background: There is a lack of clinically available predictive models for patients with epidermal growth factor receptor (EGFR) mutation positive, advanced non–small cell lung cancer (NSCLC) treated with EGFR‐tyrosine kinase inhibitors (TKIs). Methods: The clinical data of patients at the Cancer Hospital, Chinese Academy of Medical Sciences between from January 2016 to January 2021 were retrospectively retrieved as training set. The patients from BENEFIT trial were for the validation cohort. The nomogram was built based on independent predictors identified by univariate and multivariate Cox regression analyses. The discrimination and calibration of the nomogram were evaluated by C‐index and calibration plots. Results: A total of 502 patients with complete clinical data and follow‐up information were enrolled in this study. Five independent prognostic factors, including The Eastern Cooperative Oncology Group Performance Status scale (ECOG PS), EGFR mutation subtype, EGFR co‐mutation, liver metastasis and malignant pleural effusion ( p < 0.05). The C‐indexes of the nomogram were 0.694 (95% confidence interval [CI], 0.663–0.725) for the training set and 0.653 (95% CI, 0.610–0.696) for the validation set. The calibration curves for the probabilities of 9‐, 12‐ and 18‐month progression‐free survival (PFS) revealed satisfactory consistency in both the internal and external validations. Additionally, the patients were divided into two groups according to risk (high‐risk, low‐risk), and significant differences in PFS were observed between the groups in the training and external validation cohorts ( p < 0.001). Conclusions: We constructed and validated a convenient nomogram that have the potential to become an accurate and reliable tool for patients with EGFR mutation positive, advanced NSCLC to individually predict their potential benefits from EGFR‐TKIs, and facilitate clinical decision‐making.

20 September 2022 in Thoracic Cancer
Verified
Journal Article
Open access
GCGeyun Chang
Geyun Chang
WLWeihua Li
Weihua Li
HBHua Bai
Hua Bai
JDJian Chun Duan
Jian Chun Duan
ZWZhijie Wang
Zhijie Wang
JWjie wang
jie wang
Background: The switch/sucrose nonfermentable complex mutations (SWI/SNF‐mut) are common in non–small cell lung cancer (NSCLC). However, the association of SWI/SNF‐mut with the clinical outcomes of immune checkpoint inhibitors (ICIs), particularly of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs), has not been established.Methods: We retrospectively collected data of patients at Cancer Hospital Chinese Academy of Medical Sciences. Patients with advanced NSCLC who received programmed cell death protein‐1 or programmed cell death ligand 1 (PD‐[L]1) inhibitors were included in cohort 1 and those with EGFR mutations (EGFR‐mutant) received EGFR‐TKIs monotherapy were included in cohort 2. Two reported Memorial Sloan‐Kettering Cancer Center (MSKCC) cohorts received immunotherapy alone used as the validation for cohort 1. We analyzed the relationship between SWI/SNF alterations and clinical outcomes in each cohort.Results: In total, 1162 patients were included, of which 230 patients (19.8%) were identified as SWI/SNF‐mut with the most common genetic alterations being ARID1A (33.4%) and SMARCA4 (28.3%). In cohort 1 (n = 146), patients with co‐mutations of SWI/SNF and Kirsten rat sarcoma oncogene (KRAS) (SWI/SNFmutKRASmut, n = 18) had significantly prolonged progression‐free survival (PFS) (8.6 m vs. 1.9 m; hazard ratio [HR], 0.31; 95% confidence intervals [CI], 0.11–0.83; p = 0.032) to PD‐(L)1 inhibitors monotherapy, which was consistent with the MSKCC cohorts (not reach [NR] vs. 6.3 m; HR, 0.36, 95% CI, 0.15–0.82; p = 0.016). In cohort 2 (n = 205), ARID1A‐mut (n = 16) was associated with improved PFS after EGFR‐TKIs (20.6 m vs. 11.2 m; HR, 0.47, 95% CI, 0.27–0.94; p = 0.023).Conclusions: In advanced NSCLC, patients with SWI/SNFmutKRASmut seem to benefit more from ICIs. Furthermore, ARID1A‐mut may provide a protective effect to EGFR‐TKIs in EGFR‐mutant patients. However, this is a retrospective single‐institution analysis that requires further validation by large prospective studies.